Hoth Therapeutics expands intellectual property portfolio for HT-001

Hoth Therapeutics (HOTH) announced the expansion of its intellectual property portfolio for HT-001, its lead topical therapeutic candidate. The Company has filed multiple U.S. Provisional Patent Applications covering novel dermatological indications, broadening the commercial and clinical potential of HT-001. The filings include: Treatment of Drug-Induced Hypersensitivity Syndrome; Treatment of Radiotherapy-Induced Rash; Treatment of Dermatological Conditions Associated with MENIN Inhibitor Therapy. MENIN inhibitors are an emerging class of targeted oncology drugs designed to block the interaction between the menin protein and MLL1/KMT2A fusion proteins – genetic drivers implicated in acute leukemias and other cancers. Early clinical data from leading oncology companies have shown that MENIN inhibitors can induce strong antitumor activity, making them one of the most closely watched new therapeutic classes in cancer drug development. However, patients receiving MENIN inhibitors frequently experience significant dermatological side effects, including painful or disfiguring rashes that can lead to dose reductions or treatment discontinuation. These adverse events may limit the full therapeutic potential of MENIN inhibitor therapy.